에 대한 최신 뉴스 Legend Biotech (NASDAQ:LEGN) 주식

Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Large Cap

News

Movers

General

COIN

EPAM

INFY

LEGN

MSTR

TOST

VTRS

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?

워너 브라더스와 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 14일-7월 20일)

Legend Biotech Corporation - American Depositary Shares

Legend Biotech Corp

Whales with a lot of money to spend have taken a noticeably bullish stance on Astera Labs.
Looking at options history for Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) we detected 30 trades.
If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $186,638 and 26, calls, for a total amount of $1,546,190.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $52.5 to $200.0 for Astera Labs over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Astera Labs stands at 679.4, with a total volume reaching 9,028.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Astera Labs, situated within the strike price corridor from $52.5 to $200.0, throughout the last 30 days.
<h3>Astera Labs Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737656128_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$12.8</td>
<td>$12.7</td>
<td>$12.8</td>
<td>$115.00</td>
<td>$179.2K</td>
<td align="right">84</td>
<td align="right">239</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.7</td>
<td>$13.6</td>
<td>$14.4</td>
<td>$200.00</td>
<td>$144.0K</td>
<td align="right">12</td>
<td align="right">103</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.7</td>
<td>$12.6</td>
<td>$12.7</td>
<td>$120.00</td>
<td>$127.0K</td>
<td align="right">23</td>
<td align="right">186</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$15.0</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$110.00</td>
<td>$108.0K</td>
<td align="right">214</td>
<td align="right">453</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$14.8</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$110.00</td>
<td>$102.9K</td>
<td align="right">214</td>
<td align="right">531</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.
<h3>Current Position of Astera Labs</h3>
<ul>
<li>With a trading volume of 3,777,557, the price of ALAB is down by -3.97%, reaching $118.06.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 18 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $136.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Northland Capital Markets downgraded its action to Market Perform with a price target of $120. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Astera Labs with a target price of $150. 
&#x2A; In a cautious move, an analyst from Morgan Stanley downgraded its rating to Equal-Weight, setting a price target of $142. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Astera Labs, which currently sits at a price target of $135. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Astera Labs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

ALAB

Smart Money Is Betting Big In ALAB Options

Financial giants have made a conspicuous bullish move on Electronic Arts. Our analysis of options history for Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) revealed 21 unusual trades.
Delving into the details, we found 57% of traders were bullish, while 28% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $858,410, and 9 were calls, valued at $517,095.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $145.0 for Electronic Arts, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Electronic Arts stands at 64.5, with a total volume reaching 12,625.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Electronic Arts, situated within the strike price corridor from $90.0 to $145.0, throughout the last 30 days.
<h3>Electronic Arts 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737656123_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$19.4</td>
<td>$18.6</td>
<td>$18.5</td>
<td>$138.00</td>
<td>$185.0K</td>
<td align="right">292</td>
<td>221</td>
</tr>
<tr>
<td>EA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.65</td>
<td>$1.75</td>
<td>$105.00</td>
<td>$175.0K</td>
<td align="right">32</td>
<td>1.5K</td>
</tr>
<tr>
<td>EA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/31/25</td>
<td>$9.0</td>
<td>$8.6</td>
<td>$8.8</td>
<td>$110.00</td>
<td>$168.0K</td>
<td align="right">0</td>
<td>208</td>
</tr>
<tr>
<td>EA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.15</td>
<td>$1.8</td>
<td>$1.9</td>
<td>$105.00</td>
<td>$95.0K</td>
<td align="right">32</td>
<td>523</td>
</tr>
<tr>
<td>EA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.8</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$115.00</td>
<td>$86.4K</td>
<td align="right">36</td>
<td>332</td>
</tr>
</tbody>
</table>

<h3>About Electronic Arts</h3>
Electronic Arts is one of the largest global developers and publishers of video games. Its most important franchises are the Madden NFL and FC soccer games, which it releases annually. In 2024, it also relaunched its American college football game. Other major franchises include Apex Legends, Battlefield, and The Sims. Typically, about three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales.
In light of the recent options history for Electronic Arts, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Electronic Arts's Current Market Status</h3>
<ul>
<li>With a volume of 11,948,472, the price of EA is down -16.67% at $118.61. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Electronic Arts options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Electronic Arts's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PINS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Pinterest.
This isn't normal.
The overall sentiment of these big-money traders is split between 56% bullish and 31%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $313,543, and 10 are calls, for a total amount of $735,123.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $42.0 for Pinterest over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pinterest's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pinterest's significant trades, within a strike price range of $20.0 to $42.0, over the past month.
<h3>Pinterest Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737656118_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.46</td>
<td>$1.44</td>
<td>$1.46</td>
<td>$40.00</td>
<td>$261.9K</td>
<td>460</td>
<td>2.0K</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.55</td>
<td>$30.00</td>
<td>$138.7K</td>
<td>1.9K</td>
<td>262</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.94</td>
<td>$0.91</td>
<td>$0.91</td>
<td>$29.00</td>
<td>$79.8K</td>
<td>8.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$12.5</td>
<td>$10.85</td>
<td>$12.44</td>
<td>$20.00</td>
<td>$64.6K</td>
<td>81</td>
<td>52</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.96</td>
<td>$0.92</td>
<td>$0.92</td>
<td>$29.00</td>
<td>$59.2K</td>
<td>8.1K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Pinterest</h3>
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.
Following our analysis of the options activities associated with Pinterest, we pivot to a closer look at the company's own performance.
<h3>Where Is Pinterest Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 5,736,507, the PINS's price is up by 2.73%, now at $32.51. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>What The Experts Say On Pinterest</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $36.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Pinterest with a target price of $37. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Pinterest with a target price of $36. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Pinterest with a target price of $39. 
&#x2A; In a cautious move, an analyst from Jefferies downgraded its rating to Hold, setting a price target of $32. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pinterest with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

PINS

Pinterest Options Trading: A Deep Dive into Market Sentiment

Trading Ideas

MCTR

CTRL Group Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 148%

Four days into his second term, President Donald Trump addressed the World Economic Forum 2025 in Davos via video conference on Thursday, outlining an aggressive economic agenda that promises corporate tax cuts, deregulation, energy expansion and a hardline stance on global trade.
In a speech that underscored his America-first approach, Trump vowed to reverse the policies of the previous administration and position the U.S. as a global leader in energy, artificial intelligence and manufacturing.
Here are five key takeaways from Trump's remarks at WEF 2025:
<h3 class="wp-block-heading">1. From Green To Black: Trump's Energy Pivot To Power The AI Boom</h3>
Trump reiterated an energy policy aimed at ramping up domestic oil and gas production, a stark reversal from the climate policies of the Biden administration.
"I terminated the ridiculous and incredibly wasteful Green New Deal, I call it the Green New Scam," he said, signaling a complete break from global decarbonization efforts.
With AI poised to reshape the global economy, Trump argued that America needs to double its energy output to support the industry&#8217;s power-intensive infrastructure. 
"The United States has the largest amount of oil and gas of any country on Earth, and we&#8217;re going to use it," he said. 
His administration is accelerating permits for oil and gas drilling, LNG terminals and coal plants, he said, arguing that these resources will lower energy costs and fuel AI infrastructure.
Trump also linked high energy prices to the Russia-Ukraine war. "If the price came down, the Russia-Ukraine war would end immediately." He vowed to pressure Saudi Arabia and OPEC to lower costs.
<h3 class="wp-block-heading">2. AI, Tech Investments Surge Amid Deregulation Blitz</h3>
Trump envisions the U.S. as the &#8220;world capital of artificial intelligence,&#8221; citing major corporate investments, including a $500 billion commitment from Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), SoftBank and OpenAI for the Stargate project.
To supercharge this expansion, he vowed to cut regulatory red tape, promising the largest deregulation campaign in U.S. history.
"My administration has also begun the largest deregulation campaign ever," he said, pledging to eliminate 10 old regulations for every new one introduced. 
The goal? Fast-track AI and tech infrastructure, including data centers, semiconductor plants and energy projects.
Trump&nbsp;criticized what he said were&nbsp;burdensome regulations under the Biden administration, which he&nbsp;said&nbsp;added $50,000 in extra costs per household and stifled economic growth.
<h3 class="wp-block-heading">3. Corporate Taxes Slashed Up To 15%, But Only For &#8216;Made In US&#8217;</h3>
Trump said corporate taxes will be cut from 21% to 15%, but only for companies that manufacture in the U.S., though Congressional approval is necessary to undertake these cuts.
"My message to every business in the world is very simple: Come make your product in America, and we will give you among the lowest taxes of any nation on Earth."
For companies that continue to manufacture abroad, Trump warned of steep tariffs designed to funnel "hundreds of billions, even trillions of dollars" into the U.S. economy. The move is aimed at boosting domestic production, job creation and reducing trade deficits.
<h3 class="wp-block-heading">4. Trade Tensions Remain High</h3>
Trump took aim at trade policies, singling out the European Union, China and Canada for what he called unfair treatment of the U.S. economy.
He slammed the EU's &#8220;cumbersome&#8221; regulatory system, which he said stifles growth and restricts American exports. He also criticized EU tariffs on American goods, while allowing European exports to flood the U.S. market.
 "We have hundreds of billions of dollars of deficits with the EU, and nobody&#8217;s happy with it," Trump warned, signaling potential retaliatory tariffs. 
Despite maintaining that he has a good relationship with Chinese President Xi Jinping, Trump insisted that trade must be &#8220;fair&#8221; and warned that tariffs will be a key tool in future negotiations.
"We just want fairness. We don't have to make it phenomenal, we just have to make it fair," he said, leaving the door open for potential trade talks but with a strong emphasis on protecting U.S. industries. 
On Canada, Trump criticized the trade imbalance between the two nations. "We don't need their oil and gas. We have more than anybody."
He went even further, saying that Canada could avoid tariffs if it became a U.S. state. "If you're a state, we won't have a deficit, we won't have to tariff you," Trump said.
<h3 class="wp-block-heading">5. Inflation, Interest Rates: Trump Demands Immediate Rate Cuts</h3>
Trump blamed runaway government spending for what he called "the worst inflation crisis in modern history,&#8221; blaming $8 trillion in deficit spending under the Biden administration as the main culprit.
He highlighted that inflation remains 50% above target, with soaring food and consumer prices straining American households. 
To combat this, Trump said he has already taken swift executive action, including a federal hiring freeze, a regulation freeze and a foreign aid freeze.
On interest rates, he called for immediate cuts, linking borrowing costs to energy prices.
"With oil prices going down, I'll demand that interest rates drop immediately, and likewise, they should be dropping all over the world," Trump said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43163656/stargate-project-microsoft-gains-oracle-waits-data-centers-face-long-term-questions">Stargate Project: Microsoft Gains, Oracle Waits, Data Centers Face Long-Term Questions</a></li>
</ul>
Photo: Shutterstock

Asia

Eurozone

Politics

Global

Econ #s

Economics

ORCL

Trump Outlines Economic Reset At Davos: 5 Things You Need To Know

Trading in Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) is quiet Thursday. The stock is consolidating after<a href="https://www.benzinga.com/general/space/25/01/43114574/rocket-lab-shares-are-on-the-rise-today-whats-going-on"> a recent large move higher. </a>
The move was driven by optimistic investors who believe President Donald Trump's efforts to fund the United States Space Force will benefit the company.
Shares may be breaking out and setting up for another uptrend. This is why it is Benzinga&#8217;s Stock of the Day.
There is a common perception among some analysts that technical analysis is not a reliable method, but when applied and understood correctly, it is the study of supply and demand in a market.
If a stock is trending higher, it's because there is more demand than supply. Investors and traders who wish to acquire shares are forced to pay premiums and outbid others. This puts the stock into an uptrend.
Resistance is a large concentration of sellers who are looking to sell at or close to the same price. There's enough supply to fill all of the demand. This is why rallies pause or end when they reach resistance. As you can see on the chart, the $29 level has been resistance for Rocket Lab.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="551" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23130232/rklb-1-1024x551.png" alt="" class="wp-image-747487" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23130232/rklb-1-1024x551.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23130232/rklb-1-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23130232/rklb-1-768x413.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23130232/rklb-1.png 1525w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/25/01/43169109/blackrocks-larry-fink-warns-that-new-inflationary-pressures-could-shock-the-stock-market-it-could-be-pretty-bad">BlackRock&#8217;s Larry Fink Warns That New Inflationary Pressures Could &#8216;Shock&#8217; The Stock Market: &#8216;It Could Be Pretty Bad&#8217;</a>
Sometimes, stocks head lower after reaching resistance. This is what happened in early January.
This price action occurs when anxious sellers start to undercut each other. This can result in a snowball effect that forces the stock down
But sometimes, the buyers can overpower the sellers and push the price above the resistance. This is called a breakout. It could set the stage for another move higher.
If the stock consolidates after the breakout and the price level that had been resistance converts into support, it tends to be the beginning of a new uptrend, which looks to be the case here.
Resistance can become support when people who sold at the resistance think they made a mistake when the resistance broke, and the stock moved higher. Some decide to repurchase their shares if they can at the same price they had been sold for.
So, if and when the stock drops back to the price that had been resistance, these remorseful sellers place buy orders. If enough of them exist, it will create support at the same price that had been resistance.
When this happens, it could signal the beginning of a new uptrend, and Rocket Lab may be on the verge of such a move.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43161311/donald-trump-has-more-than-50-of-net-worth-in-crypto-will-establish-strategic-bitcoin-reserve-anthony-pompliano-predicts">Donald Trump Has &#8216;More Than 50%&#8217; Of Net Worth In Crypto, Will Establish Strategic Bitcoin Reserve, Anthony Pompliano Predicts</a></li>
</ul>
Photo: Shutterstock

SPACE

Technicals

RKLB

Stock Of The Day: Rocket Lab's Next Move Could Signal Rally Ahead

Senator Cynthia Lummis (R-WY), known as the "<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42601193/senator-lummis-introduces-strategic-bitcoin-reserve-proposal">Crypto Senator</a>," has been named Chair of the Senate Banking Subcommittee on Digital Assets.
What Happened: This <a href="https://x.com/SenLummis/status/1882454483852255605">appointment</a> signals a renewed push by the United States to establish clear regulatory frameworks for digital assets while advancing initiatives like a U.S. strategic Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reserve, an idea championed by Lummis and supported by President Donald Trump.
"Digital assets are the future," Lummis <a href="https://x.com/SenLummis/status/1882454483852255605">said</a>, emphasizing that the U.S. must act swiftly to remain a global leader in financial innovation. 
"Congress needs to urgently pass bipartisan legislation establishing a comprehensive legal framework for digital assets and that strengthens the U.S. dollar with a strategic Bitcoin reserve."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43161311/donald-trump-has-more-than-50-of-net-worth-in-crypto-will-establish-strategic-bitcoin-reserve-anthony-pompliano-predicts">Donald Trump Has &#8216;More Than 50%&#8217; Of Net Worth In Crypto, Will Establish Strategic Bitcoin Reserve, Anthony Pompliano Predicts</a>
Why It Matters: This development follows a notable turnaround in Trump's approach to cryptocurrency.
During his first term as president, Trump was a vocal critic of Bitcoin and digital assets, famously tweeting in 2019 that he was "not a fan of Bitcoin" and criticizing its potential for misuse in illicit activities. 
His administration focused on tightening regulatory scrutiny, with agencies like the SEC and CFTC ramping up enforcement actions against unregistered offerings and crypto scams.
Trump's stance began to shift during his 2024 presidential campaign. 
Facing a reelection bid amid a growing crypto industry, he embraced digital assets as a cornerstone of his economic strategy. 
Campaigning as the "Bitcoin President," Trump pledged to establish a strategic Bitcoin reserve and promote crypto-friendly policies to modernize the U.S. financial system.
This pivot won him significant support from key figures in the crypto space, including venture capitalists, blockchain advocates and major cryptocurrency platforms.
The industry's backing played a crucial role in mobilizing young voters and tech-savvy entrepreneurs, ultimately contributing to his electoral success.
Since returning to office, Trump has doubled down on his newfound enthusiasm for digital assets. 
A substantial portion of Trump's net worth—over 50% according to crypto advocate Anthony Pompliano—is now <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43161311/donald-trump-has-more-than-50-of-net-worth-in-crypto-will-establish-strategic-bitcoin-reserve-anthony-pompliano-predicts">tied to cryptocurrency holdings.</a>
The president's involvement extends to the meme coin phenomenon, with the launch of the Trump-themed meme coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) and another dedicated to First Lady Melania Trump (CRYPTO: MELANIA). 
However, TRUMP is currently down 51% in last 4 days from $75 to $36.
Melania is down 80% in the last 3 days from $13.73 to $2.57.
As Chair of the Digital Asset Subcommittee, Lummis is uniquely positioned to advance crypto policy in alignment with Trump's pro-crypto agenda. 
Representing Wyoming, a state renowned for its blockchain-friendly legislation, Lummis has long advocated for a balanced approach to regulation.
Her leadership is expected to prioritize bipartisan legislation addressing stablecoin oversight, decentralized finance (DeFi) rules and clearer registration pathways for crypto projects.
Additionally, her call for a strategic Bitcoin reserve aims to position the U.S. as a global leader in digital asset adoption.
Binance CEO Changpeng Zhao praised Lummis' appointment, <a href="https://x.com/cz_binance/status/1882457079769891188">tweeting</a>, "US Strategic Bitcoin Reserve, pretty much confirmed. Crypto moving at crypto speed again."
Read Next: 
<ul>
<li><a style="font-weight: bold;" href="https://www.benzinga.com/25/01/43156012/evaa-protocol-secures-25m-in-private-token-sale-to-expand-ton-defi-embargo-ends-at-12pm-cet">EVAA Protocol Secures $2.5M In Private Token Sale To Expand TON DeFi</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$TRUMP

'Crypto Senator Lummis' To Chair Senate Banking Digital Assets Subcommittee: Is The Bitcoin Reserve On Its Way?

Analyst Ratings

CWEN

NDAQ

CNBC Halftime Report Final Trades: Freeport-McMoRan, Clearway Energy, Nasdaq

Ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.42, along with a high estimate of $190.00 and a low estimate of $152.00. Experiencing a 2.74% decline, the current average is now lower than the previous average price target of $171.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655263_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Johnson &amp; Johnson's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$166.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$162.00</td>
<td>$156.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Johnson &amp; Johnson's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Johnson &amp; Johnson's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Breaking Down Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Johnson &amp; Johnson showcased positive performance, achieving a revenue growth rate of 5.25% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Johnson &amp; Johnson's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average. With a ratio of 0.51, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Johnson & Johnson Stands With Analysts

Across the recent three months, 5 analysts have shared their insights on OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $50.0, with a high estimate of $55.00 and a low estimate of $45.00. Surpassing the previous average price target of $48.80, the current average has increased by 2.46%.
<img src="https://www.benzinga.com/files/images/story/2025/1737655248_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of OFG Bancorp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OFG Bancorp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OFG Bancorp compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of OFG Bancorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OFG Bancorp's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OFG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OFG Bancorp analyst ratings.</a>
<h2>Delving into OFG Bancorp's Background</h2>
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. It provides services in the region of Puerto Rico.
<h3>OFG Bancorp: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, OFG Bancorp showcased positive performance, achieving a revenue growth rate of 2.24% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 28.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): OFG Bancorp's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.41%, the company showcases effective utilization of assets.
Debt Management: OFG Bancorp's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About OFG Bancorp

The Leuthold Group just gave investors something new to talk about with the launch of<a href="https://www.benzinga.com/etfs"> its latest ETF</a>, the Leuthold Select Industries ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LST#NYSE">LST</a>). This ETF is the result of an evolution of the Leuthold Select Industries Fund, a mutual fund of more than 20 years that covers everything from small-cap up-and-comers to well-established bigwigs.
Instead of sticking to broad sectors, the fund zeroes in on specific industry groups — about 120. The idea? Find those pockets of the market where companies are poised to outperform.
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/01/43160029/tesla-nvidia-etfs-in-the-works-to-tap-rising-interest-in-same-day-stock-options">Tesla, Nvidia ETFs In The Works To Tap Rising Interest In Same-Day Stock Options</a>
"With LST, equity investors who want exposure to a longstanding, proven investment discipline — coupled with the lower cost, operational ease and tax benefits of an ETF — will have that opportunity," said Leuthold CIO Doug Ramsey. "We've been pleased with the performance and market reception of LCR, so it was a natural progression to convert Select Industries to an ETF."
This isn't the Leuthold Group's first time in the ETF space. Their Leuthold Core ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCR#NYSE">LCR</a>) has become popular, blending equity and fixed-income assets. The ETF has more than $80 million in assets under management and a five-star Morningstar rating from the Leuthold Select Industries Fund.
The Leuthold Select Industries ETF comes with a net expense ratio of 0.65%, thanks to a fee waiver. That's a reasonable deal for a fund offering this level of specialization. With markets expected to broaden their growth across sectors in 2025, the ETF is expected to benefit from focusing on advantageous industries. 
The ETF is ideal for investors looking to grow their money over the long term. It is actively managed and has exposure to a broad mix of U.S.-traded equities. 
See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43159032/defiance-quantum-etf-hits-1-billion-milestone-as-ceo-talks-future-of-industry">Defiance Quantum ETF Hits $1 Billion Milestone As CEO Talks Future Of Industry</a></li>
</ul>
Photo: Shutterstock

Long Ideas

New ETFs

ETFs

Managed Portfolio Series Leuthold Select Industries ETF

Leuthold Group Introduces Select Industries ETF, Focus On Companies Ready To Outperform

19 analysts have shared their evaluations of SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.78, along with a high estimate of $21.00 and a low estimate of $3.90. A decline of 25.74% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655240_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of SolarEdge Technologies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$3.90</td>
<td>$3.90</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$12.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SolarEdge Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of SolarEdge Technologies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of SolarEdge Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of SolarEdge Technologies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEDG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SolarEdge Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About SolarEdge Technologies</h2>
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
<h3>Financial Milestones: SolarEdge Technologies's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: SolarEdge Technologies's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -64.03%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: SolarEdge Technologies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -461.98%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SolarEdge Technologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -78.71%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SolarEdge Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -35.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.79, SolarEdge Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEDG

19 Analysts Assess SolarEdge Technologies: What You Need To Know

In the latest quarter, 3 analysts provided ratings for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $248.67, with a high estimate of $280.00 and a low estimate of $206.00. This upward trend is apparent, with the current average reflecting a 3.61% increase from the previous average price target of $240.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737655229_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Align Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$260.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Michael Ryskin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$206.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Align Tech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Align Tech compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Align Tech's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Align Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Align Tech analyst ratings.</a>
<h2>All You Need to Know About Align Tech</h2>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
<h3>Financial Milestones: Align Tech's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Align Tech's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.84%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Align Tech's net margin is impressive, surpassing industry averages. With a net margin of 11.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.85%, the company showcases effective utilization of assets.
Debt Management: Align Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGN

The Analyst Verdict: Align Tech In The Eyes Of 3 Experts

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Waste Management, revealing an average target of $232.0, a high estimate of $252.00, and a low estimate of $219.00. This current average reflects an increase of 3.22% from the previous average price target of $224.77. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655222_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Waste Management. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$238.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$252.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Coleman</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Jeffrey Goldstein</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$227.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$228.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$220.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Stephanie Yee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$226.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$220.00</td>
<td>$213.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waste Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waste Management compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Waste Management's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Waste Management's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waste Management analyst ratings.</a>
<h2>About Waste Management</h2>
WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 263 active landfills and about 332 transfer stations. The company serves residential, commercial, industrial, and medical end markets and is also a leading recycler in North America.
<h3>Waste Management: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Waste Management displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.91%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Waste Management's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.85%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Waste Management's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.09.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Waste Management: 13 Analysts Share Their Views

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) underwent analysis by 19 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">14</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.63, a high estimate of $95.00, and a low estimate of $60.00. This current average has decreased by 5.94% from the previous average price target of $78.28. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655212_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Exact Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Nowark</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exact Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exact Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.78%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exact Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exact Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXAS

Forecasting The Future: 19 Analyst Projections For Exact Sciences

Looking into the current session, International Seaways Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) shares are trading at $36.49, after a 0.43% increase. Moreover, over the past month, the stock went up by 1.32%, but in the past year, fell by 31.56%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1737655209_0.png" alt="Past Year Chart" />

<h3>A Look at International Seaways P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 26.02 in the Oil, Gas &amp; Consumable Fuels industry, International Seaways Inc. has a lower P/E ratio of 3.52. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1737655209_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

INSW

Price Over Earnings Overview: International Seaways

<a href="https://www.benzinga.com/topic/gold">Gold prices surged</a> to near three-month highs this week, with spot gold reaching $2,755.2 per ounce on Jan. 22, just below its record peak of $2,790.15 from Oct. 31, 2024.
What Happened: As President Donald Trump's tariff announcements reverberate through global markets, gold, often seen as a safe haven during uncertain times, has reclaimed the spotlight. Two of the <a href="https://www.benzinga.com/etfs">most prominent ETFs</a>, SPDR Gold Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) and iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) offer exposure to gold with different features to suit various investor profiles.
Both ETFs use the same benchmark: the LBMA (London Bullion Market Association) Gold Market Fixing Price PM Index.
The SPDR Gold Shares ETF is priced at around $244 per share with a 0.40% expense ratio. The ETF appeals to investors seeking high liquidity and trust in a well-established product. Trading volume of the ETF is hefty, making it especially attractive for frequent traders. However, its higher expense ratio and market price may deter cost-conscious retail investors.
The iShares Gold Trust ETF, on the other hand, is priced at around $50 per share with a lower 0.25% expense ratio. It offers a more economical entry point for gold investors. Although no match for GLD&#8217;s trading volume, IAU is still highly liquid and considered a viable choice for retail investors.
See Also: <a href="https://www.benzinga.com/news/large-cap/25/01/43137560/golds-blowout-rally-puts-spotlight-on-miners-will-they-finally-catch-up">Gold&#8217;s Blowout Rally Puts Spotlight On Miners: Will They Finally Catch Up?</a> 
Why It Matters: The rally is fueled by a weaker dollar and growing uncertainty surrounding Trump's proposed policies, including sweeping tariffs. Some investors fear his decisions will trigger trade wars and heighten market volatility.
Gold, as ever, remains a safe bet for risk-averse investors. While physical bullion remains a traditional choice, its limitations— such as storage costs, premiums, and liquidity challenges — make gold ETFs a more practical alternative for modern investors.
Although gold prices pulled back slightly today, it is possible that this is due to traders booking profits after the sharp ascent, and the movement is still bullish for the metal.
A walk down the memory lane shows us that gold has historically thrived during Trump&#8217;s presidency. When he assumed office in 2017, gold prices were near $1,200 per ounce, soaring to $1,957 per ounce by January 2021, as pointed out in a report in FXEmpire.
Now, in Trump's second term, the &#8220;Tariff Man&#8221; — a self-proclamation he made during his first term — is <a href="https://www.benzinga.com/government/regulations/25/01/43162941/trumps-second-term-sparks-market-jitters-with-trade-regulation-expansion-plans">introducing aggressive policies</a>, further stoking uncertainty. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#8230;.I am a Tariff Man. When people or countries come in to raid the great wealth of our Nation, I want them to pay for the privilege of doing so. It will always be the best way to max out our economic power. We are right now taking in $billions in Tariffs. MAKE AMERICA RICH AGAIN
&mdash; Donald J. Trump (@realDonaldTrump) <a href="https://twitter.com/realDonaldTrump/status/1069970500535902208?ref_src=twsrc%5Etfw">December 4, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His proposals to impose 25% tariffs on Mexico and Canada by Feb. 1 and to levy a <a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1">10% tariff on Chinese imports</a> could impact global trade dynamics.
Just an example of why the markets are volatile, Canada is one of the world's largest producers of gold and a GSC Commodity Intelligence study revealed that the U.S. is the world&#8217;s largest importer of Canadian gold. A 25% tariff on imports from Canada might impact overall U.S. imports. See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43159032/defiance-quantum-etf-hits-1-billion-milestone-as-ceo-talks-future-of-industry">Defiance Quantum ETF Hits $1 Billion Milestone As CEO Talks Future Of Industry</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

SPDR Gold Shares Vs. iShares Gold Trust: Two Shiny ETFs In Focus As 'Tariff Man' Trump Fuels Uncertainty

Raymond James analyst John Freeman maintains Kimbell Royalty Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>) with a Strong Buy and raises the price target from $19 to $23.

Price Target

Raymond James Maintains Strong Buy on Kimbell Royalty Partners, Raises Price Target to $23

CTRL Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 113.6%

Raymond James analyst John Freeman maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Strong Buy and raises the price target from $167 to $175.

Raymond James Maintains Strong Buy on EOG Resources, Raises Price Target to $175

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Legend Biotech (LEGN – Research Report) and NewAmste...

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)

Analyst Kostas Biliouris from BMO Capital reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price target at $90.00...

Promising Growth Trajectory and Market Expansion Justify Buy Rating for Legend Biotech

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

A rumor regarding Legend Biotech (LEGN) was highlighted in an alert sent to subscribers of Ben Harrington's takeover-focused Betaville blog, contac...

Legend Biotech rumor highlighted in Betaville alert

Legend Biotech surges amid takeover speculation

The latest update is out from Legend Biotech ( ($LEGN) ). Legend Biotech announced the availability of an updated corporate presentation at the 43r...

Legend Biotech Showcases CAR-T Therapy Success at J.P. Morgan Healthcare Conference

Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness

BMO Capital analyst Kostas Biliouris has maintained their bullish stance on LEGN stock, giving a Buy rating yesterday. Kostas Biliouris has given h...

Legend Biotech's Carvykti Receives Buy Rating Amid Improved Safety Profile and Projected Sales Growth

Legend Biotech ( ($LEGN) ) just unveiled an update. On January 22, 2025, Legend Biotech announced preliminary sales figures for CARVYKTI&#xAE; for the q...

Legend Biotech Reports Q4 CARVYKTI® Sales

Goldman Sachs lowered the firm's price target on Legend Biotech (LEGN) to $84.28 from $92.97 and keeps a Buy rating on the shares. The firm is revi...

Legend Biotech price target lowered to $84.28 from $92.97 at Goldman Sachs

BAYZF

LGND

NAMS

Press Releases

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Health Care

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Earnings

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alkermes

Alvotech

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

HC Wainwright & Co.

Piper Sandler

Cantor Fitzgerald

RBC Capital

Redburn Atlantic

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/39838603" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">기존 텔레비전 네트워크</a>에서 디지털 스트리밍 및 스튜디오 사업을 분할하려는 계획을 논의했다는 보고 이후 18.28% 상승했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 지난주 비트코인 가격의 상승 속에서 16.74% 상승했다.</li>
<li>D.R. 호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 FY24 지침을 수정한 후 12.91% 급등했다. 회사는 또한 <a href="https://www.benzinga.com//node/39845136" target="_blank" rel="noreferrer noopener">새로운 40억 달러 규모의</a> 자사 주식 매입을 승인했다. 주식에 대한 목표 주가를 <a href="https://www.benzinga.com/quote/dhi/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>을 한 분석가는 거의 없다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 지난주 비트코인 가격 상승의 영향으로 12.39% 상승했다.</li>
<li>블루 아울 캐피털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OQL#NYSE">OQL</a>)은 블룸버그가 아탈라야(Atalaya)를 약 8억 달러에 매수할 계획이라고 <a href="https://www.bloomberg.com/news/articles/2024-07-16/blue-owl-to-buy-private-credit-firm-atalaya-adding-10-billion-in-assets?sref=2h1zKciy" target="_blank" rel="noreferrer noopener">발표</a>한 후 7.89% 상승했다.</li>
<li>유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)의 주가는 <a href="https://www.benzinga.com//node/39790051" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 실적 호조</a>에 따라 7.84% 상승했다. 많은 분석가들이 주식에 대한 가격 예측을 <a href="https://www.benzinga.com//node/39814804" target="_blank" rel="noreferrer noopener">상향 조정했</a>다.</li>
<li>스테이트 스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>)는 예상보다 나은 <a href="https://www.benzinga.com//node/39795949" target="_blank" rel="noreferrer noopener">2분기</a> 실적에 힘입어 7.21% 급등했다. 몇몇 분석가들은 주식 가격 예측을 <a href="https://www.benzinga.com//node/39822388" target="_blank" rel="noreferrer noopener">수정</a>했다. </li>
<li>레나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)는 다른 주택 건설업체 주식들과의 공감을 이유로 7.07% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)는 미즈호(Mizuho)가 주식을 중립에서 아웃퍼폼(Outperform)으로 <a href="https://www.benzinga.com/quote/TOST/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">상향 조정하고</a> 목표 주가를 21달러에서 33달러로 상향 조정한 후 지난주 주가는 7.05% 상승했다. </li>
<li>이팸 시스템(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)의 주식은 제프리스(Jefferies)의 분석가가 <a href="https://www.benzinga.com/quote/epam/analyst-ratings" target="_blank" rel="noreferrer noopener">보유에서 매수로</a> 등급을 올린 후 6.97% 상승했다.</li>
</ol>
사진=Shutterstock의 rafapress






Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Legend Biotech

뉴스

에 대한 최신 뉴스 Legend Biotech (NASDAQ:LEGN) 주식

월요일, 7월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌